Cutaneous Squamous Cell Carcinoma - Updates in Immunotherapy presented by Dr. Butler MD 

Watch a live recording of our recent webinar with Dr. Marcus Butler, MD on the "Evolving Landscape of Cutaneous Squamous Cell Carcinoma Treatment: Updates on Immunotherapy Treatment"
Cutaneous Squamous Cell Carcinoma (cSCC) is the second most common form of skin cancer in Canada, with an estimated 16,000+ patients nationally. It is forecasted that anywhere from 200-700 of these patients have locally advanced or metastatic cSCC.
This livestreaming program targets surgeons from a number of specialties that are involved in the treatment of cSCC patients, to advise on a new, recently approved curative treatment. Cemiplimab is a fully-human monoclonal antibody that is the first and only biologic immunotherapy treatment specifically approved and available for adult patients with metastatic or locally advanced cSCC.
You Are Not Alone - cSCC patient support
www.melanomane...
Download a copy of our cSCC patient guide - Helping You Understand cutaneous Squamous Cell Carcinoma (cSCC) A Patient Guide
www.melanomane...
cSCC Treatment information
www.melanomane...
About Dr. Marcus Butler
Dr. Marcus Butler, MD
Medical Oncologist, Princess Margaret Cancer Centre,
University Health Networ
Melanoma Network of Canada
www.melanomane...
1.877.560.8035
info@melanomanetwork.ca
Facebook
/ melanomanetwork
Twitter
/ melanomanetwork
Instagram
/ melanomanetwork